Multiple Sclerosis Trial, Recruiting NCT06796504 Sponsor: SetPoint Medical Corporation Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06796504
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 22 and 50 years old at the time of signing up for the trial
  • You have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS where symptoms come and go) using standard 2017 diagnostic guidelines
  • A specific eye test (called a visual evoked potential, or VEP) shows that signals from at least one of your eyes are traveling more slowly than normal to your brain
  • A scan of the back of your eye (called an OCT) shows that you still have enough nerve fibers remaining in the qualifying eye
  • Your best corrected vision (with glasses or contacts) is better than a certain minimum level in terms of high-contrast sight (confirm with trial site)
  • Your ability to read low-contrast letters (faint grey letters on a white background) in the qualifying eye is reduced to a certain level (confirm with trial site)
  • You have not had an MS relapse (a flare-up of symptoms) for at least 12 months before joining
  • Your most recent brain MRI (taken within the past year) shows no new or growing MS lesions
  • You have been consistently taking an MS medication (called a disease-modifying therapy) — for at least 2 years if it is a moderate-strength medication, or at least 1 year if it is a high-strength medication
  • Your level of disability, measured by a standard MS scale, falls within a specific moderate range (confirm with trial site)

Who may not be able to join:

  • You have another eye condition (such as cataracts, glaucoma, macular degeneration, or diabetic eye disease) that could interfere with eye testing
  • You have severe short-sightedness (a prescription of -6.00 diopters or stronger)
  • You have another neurological condition, including significant spinal cord problems in the neck area
  • You have had an episode of optic neuritis (inflammation of the eye nerve causing vision loss) within the past 6 months
  • You have a documented history of optic neuritis in the qualifying eye more than 5 years ago
  • You have had steroid treatment for MS symptoms in the 30 days before signing up
  • You are allergic to MRI contrast dye, or are unable to have an MRI scan (for example, due to claustrophobia)
  • You have regularly used or been dependent on nicotine products (such as cigarettes or vaping) within the past year
  • You are not considered a suitable candidate for surgery (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
SetPoint Medical Corporation
Registry
ClinicalTrials.gov
Start date
17 April 2026
Est. completion
31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov